



Epidemiologic/Population Research Group: Summary of Key Questions for Focus

Amy Justice, MD, PhD
Yale University

Vincent Lo Re, MS, MSCE
University of Pennsylvania

Key Questions: Patient-Reported Outcomes

1. What is the validity of available quality of life (QOL) tools in HIV? How differ from uninfected?

- SF-12
- HIV Medical Outcomes Survey (MOS-HIV)
- NIH Toolbox
- WHO Quality of Life Scale
- Brief Pain Scale
- PROMISE: patient-reported outcomes
- UNC CFAR: searchable lists of PRO scales

Key Questions: Prognostic Indices

- 1. What is the validity of existing prognostic indices for comorbid-specific conditions in HIV?**
 - Framingham Heart Study
 - FRAX
- 2. How well do indices generalize to subgroups?**
- 3. How differ from uninfected persons?**

Key Questions: Neurocognitive Function

- 1. What are the prevalence/incidence of neurocognitive dysfunction in HIV, by HIV suppression, subgroups?**
 - Cross-cohort collaboration, IeDEA Network
- 2. What are the phenotypes of neurocognitive dysfunction?**
- 3. What factors promote neurocognitive health in HIV vs. uninfected, people from same risk group w/o HIV?**
 - Factors: Mental health, suicidality, substance use, social determinants of health, isolation, social support
- 4. How will long-acting ART impact on neurocognitive fx?**

Key Questions: Polypharmacy in HIV

1. What are clinically relevant ARV/non-ARV drug-drug interactions leading to toxicities, mortality? Mechanisms?

- Develop methods to identify drug-drug interactions, outcomes
- How do sex, race, liver/kidney disease modify toxicity risk?
- Among HIV/cured HCV, varying levels of liver fibrosis

2. How does polypharmacy affect comorbidity risk in HIV?

1. Comorbidities: neurocognitive function, falls, hospitalization, mortality

3. What is effect of de-prescribing drugs among PLWH?

Key Questions: Frailty

1. What are valid methods to classify frailty in HIV?

- Develop, validate frailty instruments in HIV+

2. What are the underpinnings of frailty in HIV?

3. Is there a single frailty phenotype in HIV?

4. Can valid frailty instruments predict risk of outcomes?

- Can machine learning enhance clinical prediction?

Key Questions: Falls in HIV

- 1. How do how alcohol, neurocognitive active meds affect fall risk and how does this differ by HIV status?**
- 2. How does ART modify fall risk among PLWH?**
- 3. How does HIV modify interventions to reduce the risk of falls, fractures?**